Buprenorphine TDS
Total Payments
$519,100
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $519,100 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $519,100 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multi-Center Study to Evaluate the Skin Irritation and Sensitization Potential of a Vehicle Patch (for Buprenorphine Transdermal System) (Amneal Pharmaceuticals) (11749706) | Amneal Pharmaceuticals LLC | $519,100 | 0 |
Top Doctors Receiving Payments for Buprenorphine TDS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $519,100 | 3 |
Ad
Manufacturing Companies
- Amneal Pharmaceuticals LLC $519,100
Product Information
- Type Drug
- Total Payments $519,100
- Total Doctors 0
- Transactions 3
About Buprenorphine TDS
Buprenorphine TDS is a drug associated with $519,100 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Amneal Pharmaceuticals LLC.
Payment data is available from 2017 to 2017. In 2017, $519,100 was paid across 3 transactions to 0 doctors.
The most common payment nature for Buprenorphine TDS is "Unspecified" ($519,100, 100.0% of total).
Buprenorphine TDS is associated with 1 research study, including "A Multi-Center Study to Evaluate the Skin Irritation and Sensitization Potential of a Vehicle Patch (for Buprenorphine Transdermal System) (Amneal Pharmaceuticals) (11749706)" ($519,100).